Connect Biopharma is trading 10.26% up at $1.29 as investors reassess mixed September 15 Phase 2 asthma results after the stock fell 32.17% to $1.17.
- Rademikibart significantly improved Day 7 lung function and reduced treatment failures by approximately 66%, but the primary endpoint missed statistical significance.
- Data also showed fewer emergency or unscheduled visits and no new safety signals, supporting a volatile rebound.